Verisante Technology Inc. (VRSEF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Verisante Technology Inc. (VRSEF) trades at $0.0011. Verisante Technology Inc. is a Canadian company formerly focused on designing and manufacturing cancer diagnostic devices. Currently, the company does not have significant operations. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for VRSEF: VRSEF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VRSEF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on VRSEF.
How is this calculated? →Verisante Technology Inc. (VRSEF) Healthcare & Pipeline Overview
Verisante Technology Inc., based in Canada, previously engaged in the design and manufacture of cancer diagnostic devices. Currently without significant operations, the company's future direction remains uncertain within the competitive medical devices sector, where innovation and market access are critical for success.
What Is the Investment Thesis for VRSEF?
Investing in Verisante Technology Inc. (VRSEF) presents significant risks due to the company's current lack of significant operations. The company's past involvement in cancer diagnostic devices offers a glimpse into its potential, but without active operations, revenue generation is non-existent. The high beta of 4.22 indicates extreme volatility, and the negative P/E ratio of -5.11 reflects unprofitability. Any investment decision hinges on the company's ability to revitalize its operations and secure funding for future endeavors. Potential investors should closely monitor any announcements regarding strategic changes or new business initiatives. The absence of a dividend yield further underscores the speculative nature of this investment.
Based on FMP financials and quantitative analysis
VRSEF Key Highlights
Market capitalization of $0.00B indicates the company's minimal value and lack of investor confidence.
- A P/E ratio of -5.11 reflects the company's unprofitability and negative earnings.
- Beta of 4.22 suggests the stock is significantly more volatile than the market average.
- The company currently offers no dividend yield, providing no income for investors.
- The company 'does not have significant operations' indicating a pause or cessation of core business activities.
Who Are VRSEF's Competitors?
VRSEF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $2.96 | -1.66% | $19.3M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VRSEF's Key Strengths?
Previous experience in cancer diagnostic device development.
- Potential intellectual property assets.
- Established company infrastructure (if any remains).
What Are VRSEF's Weaknesses?
Lack of significant current operations.
- Limited financial resources.
- Uncertain future direction.
- Negative P/E ratio indicating unprofitability.
What Could Drive VRSEF Stock Higher?
Potential announcement of strategic partnerships or acquisitions.
- Possible restructuring or refocusing of the business strategy.
- Development and launch of new cancer diagnostic technologies.
- Monitoring of market trends and competitive landscape in the medical device industry.
What Are the Key Risks for VRSEF?
Negative return on equity (-58.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- The company's lack of significant operations poses a significant risk to investors.
- Intense competition in the medical device industry.
- Stringent regulatory requirements and potential delays in obtaining approvals.
- Technological obsolescence and the need for continuous innovation.
- Economic downturn affecting healthcare spending and demand for diagnostic devices.
What Are the Growth Opportunities for VRSEF?
- Partnerships and Acquisitions: Verisante could explore strategic partnerships with larger medical device companies or research institutions to gain access to new technologies, funding, and market channels. This could involve licensing its existing intellectual property or collaborating on the development of new diagnostic tools. The medical device industry is ripe with M&A activity, and a well-structured partnership could provide Verisante with a much-needed boost. Timeline: Within the next 12-24 months.
- Restructuring and Refocusing: Verisante could undergo a restructuring process to streamline its operations and refocus its business strategy. This could involve divesting non-core assets, reducing overhead costs, and concentrating on a specific niche within the cancer diagnostics market. A clear and focused strategy is essential for attracting investors and regaining market traction. Timeline: Within the next 6-12 months.
- New Product Development: Verisante could invest in the development of new cancer diagnostic devices that address unmet needs in the market. This could involve leveraging emerging technologies such as artificial intelligence, nanotechnology, or personalized medicine. Successful product development requires significant R&D investment and a strong understanding of market trends. Timeline: 2-3 years.
- Geographic Expansion: Verisante could expand its operations into new geographic markets, particularly in emerging economies where there is a growing demand for advanced diagnostic tools. This would require establishing distribution networks, obtaining regulatory approvals, and adapting its products to local market conditions. Timeline: 1-2 years.
- Telemedicine Integration: Verisante could integrate its diagnostic devices with telemedicine platforms to enable remote patient monitoring and diagnosis. This would allow healthcare providers to reach patients in underserved areas and improve access to care. Telemedicine is a rapidly growing field, and integration with Verisante's technology could create new revenue streams. Timeline: 1-2 years.
What Are VRSEF's Competitive Advantages?
- Potential intellectual property related to cancer diagnostic technology (if any remains).
- Prior experience in the design and manufacturing of medical devices.
- Established brand recognition (if any remains) within the cancer diagnostics market.
What Does VRSEF Do?
Verisante Technology Inc. was incorporated in 2006 and later rebranded from T-Ray Science Inc. in January 2011. Headquartered in Vancouver, Canada, the company's historical focus was on the development and production of innovative cancer diagnostic devices. While the company aimed to provide advanced tools for early cancer detection, it currently does not have significant operations. The company's previous activities centered around leveraging technology for improved diagnostic accuracy and patient outcomes. However, the company's present state indicates a pause or shift in its business strategy. The company's history reflects an ambition to contribute to the medical device industry, specifically in the area of cancer diagnostics, but its current lack of operations suggests a need for strategic reevaluation or restructuring to regain its market presence and operational capabilities. The company's future direction remains uncertain.
What Products and Services Does VRSEF Offer?
- Formerly designed and manufactured cancer diagnostic devices.
- Aimed to provide innovative tools for early cancer detection.
- Sought to improve diagnostic accuracy and patient outcomes.
- Previously operated under the name T-Ray Science Inc.
- Currently does not have significant operations.
How Does VRSEF Make Money?
- Historically, the business model focused on developing and selling cancer diagnostic devices.
- Revenue generation was likely based on direct sales to hospitals, clinics, and research institutions.
- The company may have explored licensing agreements or partnerships for technology distribution.
What Industry Does VRSEF Operate In?
Verisante Technology Inc. operates within the medical devices industry, a sector characterized by rapid technological advancements and stringent regulatory requirements. The industry is highly competitive, with established players and emerging startups vying for market share. Companies in this sector must continuously innovate to meet evolving healthcare needs and maintain a competitive edge. Given Verisante's current lack of significant operations, it faces an uphill battle to re-enter the market and compete with established companies. The medical device industry is projected to grow, driven by an aging population and increasing demand for advanced diagnostic and treatment solutions.
Who Are VRSEF's Key Customers?
- Hospitals and medical centers requiring diagnostic equipment.
- Clinics specializing in cancer screening and diagnosis.
- Research institutions conducting cancer-related studies.
Company Profile
Verisante Technology Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Thomas A. Braun. VRSEF has traded publicly since 2011.
Key Financial Metrics
Return on equity for Verisante Technology Inc. stands at -58.0%, a gauge of how efficiently it converts shareholder capital into profit. VRSEF trades at a trailing price-to-earnings ratio of 1.24, below the Healthcare sector average of ~23x. Its free cash flow yield is -13.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.11 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 80.4%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Verisante Technology Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
VRSEF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Previous experience in cancer diagnostic device development.
- Potential intellectual property assets.
- Established company infrastructure (if any remains).
- Upcoming: Potential announcement of strategic partnerships or acquisitions.
Bear Case
- Lack of significant current operations.
- Limited financial resources.
- Uncertain future direction.
- Negative P/E ratio indicating unprofitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
VRSEF Latest News
No recent news available for VRSEF.
VRSEF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VRSEF.
Price Targets
Wall Street price target analysis for VRSEF.
VRSEF MoonshotScore
What does this score mean?
The MoonshotScore rates VRSEF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Thomas A. Braun
CEO
Thomas A. Braun serves as the CEO of Verisante Technology Inc. His background likely includes experience in business management and potentially in the medical device or technology sectors. Information regarding his specific educational background and previous roles is not available in the provided data. His leadership is crucial for guiding the company through its current challenges and potential restructuring efforts.
Track Record: Due to the company's current state of limited operations, it is difficult to assess Thomas A. Braun's recent track record. His previous achievements and strategic decisions at Verisante Technology Inc. are not detailed in the provided data. The company's future performance will be a key indicator of his leadership effectiveness.
VRSEF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Verisante Technology Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in VRSEF.
- Low trading volume and wide bid-ask spreads make it difficult to execute trades.
- The OTC Other tier is associated with higher risk of fraud and manipulation.
- The company's lack of significant operations raises concerns about its long-term viability.
- The high beta of 4.22 indicates extreme price volatility.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business plan and prospects for future growth.
- Evaluate the company's competitive position within the medical device industry.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before making any investment decisions.
- The company was incorporated in 2006, indicating a history of operations.
- The company was previously involved in the design and manufacture of cancer diagnostic devices.
- The company has a CEO (Thomas A. Braun) in place.
VRSEF Healthcare Stock FAQ
What does Verisante Technology Inc. do?
Verisante Technology Inc. previously focused on the design and manufacture of innovative cancer diagnostic devices. The company aimed to improve early cancer detection and patient outcomes through advanced technology. However, currently, Verisante Technology Inc. does not have significant operations.
What do analysts say about VRSEF stock?
There is currently no available analyst coverage for VRSEF stock due to the company's limited operations and lack of financial activity. Key valuation metrics such as revenue projections and earnings estimates are not applicable in the current situation.
What are the main risks for VRSEF?
The main risks for Verisante Technology Inc. stem from its current lack of significant operations, which raises concerns about its long-term viability. The company faces intense competition in the medical device industry and must navigate stringent regulatory requirements. Additionally, technological obsolescence poses a threat, requiring continuous innovation to maintain a competitive edge.
What are the key factors to evaluate for VRSEF?
Evaluate VRSEF on fundamentals, analyst consensus, and risk factors. Investing in Verisante Technology Inc. (VRSEF) presents significant risks due to the company's current lack of significant operations. Not financial advice.
How frequently does VRSEF data refresh on this page?
VRSEF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VRSEF's recent stock price performance?
Verisante Technology Inc. (VRSEF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Previous experience in cancer diagnostic device development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VRSEF overvalued or undervalued right now?
Verisante Technology Inc. (VRSEF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VRSEF before investing?
Before investing in Verisante Technology Inc. (VRSEF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's current state.
- AI analysis is pending and may provide further insights.